IMVT - Immunovant, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$43.67
DETAILS
HIGH:
$50.00
LOW:
$40.00
MEDIAN:
$41.00
CONSENSUS:
$43.67
UPSIDE:
27.88%
About Immunovant, Inc. (https://immunovant.com)
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Tiago Girao | Chief Financial Officer | 1979 | $871,065 USD |
| William L. Macias | CMO Emeritus | 1959 | $719,876 USD |
| Jay S. Stout | Chief Technology Officer | 1964 | $683,490 USD |
| Melanie Gloria | Chief Operating Officer | 1978 | $575,913 USD |
| Christopher Van Tuyl | Chief Legal Officer & Corporate Secretary | 1976 | $549,038 USD |
| Frank Torti | Executive Chairperson of the Board | 1979 | $92,500 USD |
| Eric Venker | Chief Executive Officer & Director | 1987 | $55,000 USD |
| Andy Deig | Senior Vice President of Strategic Finance | – | – |
| Becky Merlina | Senior VP & Global Head of Quality | – | – |
| Christine Blodgett | Senior Vice President of Human Resources | – | – |
| Julie Kirschling | Senior Vice President of Program & Alliance Management | – | – |
| Sheetal Patel | Senior Vice President of Clinical Development | – | – |
| Yan Zheng | Senior Vice President of Biostatistics, Programming & Data Management | – | – |